On January 14, 2020, the FDA issued a warning against Eisai, Inc., stating that preliminary research had found that regular use of Belviq may be associated with a higher risk of developing certain type of cancers. After a more comprehensive look at the research, the FDA concluded that the elevated risk of cancer from Belviq outweighed any potential benefits the drug may have had. Therefore, on February 13, the FDA officially asked for a voluntary recall of the drug from shelves.